Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study

Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective,... Adv Ther (2017) 34:2033–2042 DOI 10.1007/s12325-017-0593-9 ORIGINAL RESEARCH Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study Mark Fajgenbaum Ejaz Ansari Received: May 28, 2017 / Published online: July 19, 2017 Springer Healthcare Ltd. 2017 40–95 years). Mean length of follow-up was ABSTRACT 56 months (range 24–180 months). Pros- taglandin analogues (PGA) were the most pop- Introduction: The purpose of this study was to ular first-line treatment in 73% of patients. As determine prescribing trends in a specialist second-line treatment, PGA were again the glaucoma clinic in the UK. Specifically, the aims predominant class, prescribed in 87% of cases, were to determine which drugs were prescribed whereas beta-blockers (BB) were prescribed in as first-, second-, and third-line treatment, the 70% of cases. Carbonic anhydrase inhibitors persistence of first-, second-, and third-line (CAI) and alpha-2 agonists (AA) were more treatment regimens, and the proportion of popular in third-line regimens. Second-line treatment decisions conforming to the Euro- treatment was introduced at a mean of pean Glaucoma Society (EGS) guidelines. 28.0 months after first-line treatment (range Methods: A retrospective, non-interventional, 1–120 months, 95% CI 22.1–33.9 months). single-center, case-note review was performed Third-line treatment was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study

Loading next page...
 
/lp/springer_journal/prescribing-trends-in-a-glaucoma-clinic-and-adherence-to-egs-Q09f0VMp2d
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by Springer Healthcare Ltd.
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0593-9
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial